Cass, This is certainly no threat to BrachySil which is to be PSD's main source of revenue in the coming years. TDS appears to be just an improvement on existing transdermal patches. IMO nothing has been demonstrated from this that would compete with PSDs proposed products. However, you cant rule this out. Like psd, they are interested in developing delivery methods that potentially could extend patent life of drugs. 10 years from now, who knows!
PSD
psivida limited
